Go to main content

GLP-1 Receptor Agonists

GLP-1 receptor agonists are a type of incretin medication that people with type 2 diabetes can use to lower blood sugar levels. 

How do GLP-1 receptor agonists work?

GLP-1 is a hormone (a natural chemical in the body) that is produced in the small intestine. It stimulates insulin secretion (which then allows cells to take up glucose) and inhibits glucagon secretion (which prevents more glucose from going into the bloodstream) to lower blood sugar levels. GLP-1 also slows stomach emptying, meaning that less glucose from food is released into the bloodstream. GLP-1s also increase satiety (how full you feel) after eating, which helps contributes to its weight loss properties.

Shorter-acting GLP-1s are particularly effective at lowering maximum glucose levels, whereas longer-acting GLP-1s have more balanced effects on lowering post-meal and fasting glucose levels.

Who uses GLP-1 receptor agonists?

GLP-1 agonists are most often used by people with type 2 diabetes to manage blood sugar levels. GLP-1s can be taken alone, or with metformin or other diabetes drugs.

GLP-1s are not approved by the FDA for people with type 1 diabetes. However, some healthcare professionals may prescribe GLP-1s off-label to those with type 1 diabetes. 

What are the benefits?

  • GLP-1s are highly effective at lowering blood glucose and A1C levels. Often, GLP-1s are given with other medications as part of a combination treatment.
  • GLP-1s can lead to significant weight loss. Some GLP-1 drugs are sold as treatments for both diabetes and obesity. For example, Ozempic (diabetes drug) and Wegovy (obesity drug) both use a GLP-1 called semaglutide and differ only in dosage.
  • Some GLP-1s have been shown to lower the risk of heart disease and kidney disease.
  • GLP-1s by themselves have a low risk of hypoglycemia. However, hypoglycemia can become a serious risk if GLP-1s are taken alongside other medications that lower blood glucose, such as sulfonylureas or insulin.

What are the drawbacks?

  • Most GLP-1s are taken by injection. The only exception is Rybelsus, an oral medication (pill).
  • Common side effects include nausea, vomiting, and diarrhea. These generally decrease over time.
  • GLP-1s are more expensive than some other glucose-lowering medications, like sulfonylureas (SFUs), metformin, and TZDs. Patient assistance programs exist which can help people who meet eligibility criteria.

Commonly used GLP-1 receptor agonist drugs:

  • Rybelsus (oral semaglutide, taken by mouth once daily)
  • Bydureon (exenatide, a once-weekly injection)
  • Ozempic (semaglutide, a once-weekly injection)
  • Trulicity (dulaglutide, a once-weekly injection)
  • Victoza (liraglutide, a once-daily injection)
  • Adlyxin (US) / Lyxumia (EU) (lixisenatide, a once-daily injection)
  • Byetta (exenatide, an injection taken twice daily)

In addition to the above GLP-1 receptor agonists, there are also other incretin drugs such as dual receptor agonists.

More information:

A woman checks her blood pressure at home.

Expert Tips for Kidney and Heart Health

Key takeaways: 

  • Kidney disease may have no symptoms, especially in the early stages, which is why screening is key. Ask your healthcare provider about yearly kidney health tests.
  • Lifestyle changes, such as monitoring blood sugar and blood pressure and medication, if needed, can help prevent kidney and heart disease.
  • If tests show a problem, ask what can be done, such as starting a new medication.
HeartLoading...

Ozempic Slows Kidney Disease, Now FDA Approved for CKD

Key takeaways:

  • People with type 2 diabetes and chronic kidney disease (CKD) who took Ozempic (semaglutide) slowed the progression of kidney disease by 24% and cut their risk of death from kidney disease.
  • Patients who took Ozempic versus placebo also cut their risk of major heart problems by 18%.
  • The latest: Newly FDA approved for CKD, Ozempic is the first GLP-1 drug that’s been approved to reduce the progression of kidney disease and risk of cardiovascular events in adults with type 2 diabetes.
HeartLoading...

Join Trial Testing New Drug for Improving A1C in Type 1 Diabetes

HeartLoading...

Zepbound Shows Greater Weight Loss Than Wegovy in Major Trial

Key takeaways:

  • In a recent clinical trial, tirzepatide achieved 47% greater weight loss compared to semaglutide.
  • More participants lost at least 25% of their initial weight on tirzepatide than on semaglutide.
  • Tirzepatide is an FDA-approved weight loss and diabetes treatment that targets both GLP-1 and GIP receptors, offering a distinct approach to weight loss and diabetes.
HeartLoading...